ClearPoint Neuro (CLPT) EBITDA (2011 - 2026)

ClearPoint Neuro (CLPT) has 15 years of EBITDA data on file, last reported at -$8.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 37.56% year-over-year to -$8.5 million; the trailing twelve-month figure through Mar 2026 stood at -$26.5 million (down 22.13% YoY), and the FY2025 full-year result was -$24.2 million, down 22.45% from the prior year.
• EBITDA retreated to -$8.5 million in Q1 2026, from -$7.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.8 million in Q3 2022 to a low of -$8.5 million in Q1 2026.
• A 5-year average of -$5.4 million and a median of -$5.2 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 77.17% in 2022 and soared 33.75% in 2024, its largest moves.
• Tracing CLPT's EBITDA over 5 years: stood at -$4.5 million in 2022, then fell by 5.3% to -$4.7 million in 2023, then declined by 19.76% to -$5.6 million in 2024, then dropped by 25.0% to -$7.0 million in 2025, then declined by 20.34% to -$8.5 million in 2026.
• Business Quant data shows CLPT's EBITDA at -$8.5 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.3 million in Q3 2025.